

2025 PDP BASIC Step Therapy Criteria

# Aggrenox - B

---

**Products Affected**

- *aspirin-dipyridamole er capsule extended release 12 hour 25-200 mg oral*

**Details**

---

<b>Criteria</b>	If the patient has tried a Step 1 drug, then authorization for a Step 2 drug will be covered. Step 1 Drug(s): clopidogrel. Step 2 Drug(s): aspirin/extended-release dipyridamole. Applies to New Starts Only.
-----------------	---

---

# Aptiom - E

---

## Products Affected

- APTIOM TABLET 200 MG ORAL
- APTIOM TABLET 400 MG ORAL
- APTIOM TABLET 600 MG ORAL
- APTIOM TABLET 800 MG ORAL

## Details

---

<b>Criteria</b>	If the patient has tried a Step 1 drug, then authorization for a Step 2 drug will be covered. Step 1 Drug(s): Lamotrigine IR, Levetiracetam IR, Oxcarbazepine IR, Topiramate IR, Zonisamide. Step 2 Drug(s): Aptiom (eslicarbazepine). Applies to New Starts Only.
-----------------	--

---

# MTX - B

---

## Products Affected

- JYLAMVO SOLUTION 2 MG/ML ORAL
- XATMEP SOLUTION 2.5 MG/ML ORAL

## Details

---

<b>Criteria</b>	If the patient has tried a Step 1 drug, then authorization for a Step 2 drug will be covered. Step 1 Drug(s): oral methotrexate sodium. Step 2 Drug(s): Jylamvo (methotrexate), Xatmep (methotrexate).
-----------------	---

---